Canopy Growth Corp (WEED)

[Beatcovid]

U.S Legeslation: Cannabis 2.0: U.S.-led consumer packaged-goods (CPG) that use cannabinoids as ingredients will drive the next leg of this secular bull market. We are at the nascent stage of this phase as consumers educate themselves on the novel end-products and various form factors, including beverages, nutraceuticals, cosmetics & vanity, and pet supplements, as well as the industrial use cases.

Cannabis 3.0: Efficacy-driven solutions will solve medical riddles across a wide range of indications and ailments and finally shift the popular perception of cannabis from a gateway drug to a wellness solution; one with a treasure trove of active pharmaceutical ingredients (API). This will follow a biotech pathway, where clinical successes drive medical adoption; GW Pharmaceuticals

We can juxtapose these buckets against the three phases of any market move: denial, migration, and panic. The sheer carnage of 1.0 and the exodus that followed has most industry followers in denial that a recovery, much less a new bull market, is possible. Banking reform will, in our view, trigger migration to the space as institutional investors chase organic growth; and demonstrated efficacious agility should, over time, turn late-cycle adopters into panic buyers of the wellness , legislation allows pension funds and other institutions to invest in this domestic secular growth story—U.S. cannabis companies will remain listed on the Canadian Stock Exchange.